Logo-antabio 中文

About Antabio

Antabio is a private French biopharmaceutical company developing a broad pipeline of novel antibacterial treatments focused on drug-resistant life-threatening infections. Antabio has built an international team of experts to understand and resolve the most urgent unmet medical needs of the antibacterial space. All Antabio’s programs address WHO critical priority pathogens and are eligible for streamlined development. Antabio’s lead program MBLi (expected to enter the clinic in 2020) addresses a critical global threat that is already highly prevalent in Asia-Pacific. The company is targeting strategic partnerships in China to maximize its peak sales potential.

Problem and solution

Antimicrobial resistance (AMR) is recognized as a global health emergency by the WHO causing 50,000 yearly deaths and healthcare costs of nearly €18 billion across EU and US alone. Alarming reports claim that by 2050, AMR will be killing more people than cancer, with a cost to the world economy of ca. $125 trillion in reduced global GDP. As antibiotic resistance genes disseminate worldwide, therapeutic options for severe hospital infections are becoming increasingly rare leading to higher mortality and morbidity rates. Furthermore, the usage of widely-used carbapenem antibiotics, considered as the cornerstone of antimicrobial chemotherapy in hospitals, is being threatened by the rapid global spread of carbapenem-degrading enzymes (“carbapenemases”) of the NDM, KPC and OXA types. The problem is reaching emergency status in China and the Asia-Pacific region where the levels of carbapenemase-mediated resistance are amongst the highest globally and increasing. A nationwide survey conducted in 2017 in China showed that the NDM metallo beta-lactamase (MBL) enzymes were already present in 31% of carbapenem-resistant Enterobacteriaceae (CRE) strains. There are no marketed inhibitors of NDMs (Zhang et al., 2017) and, while some good inhibitors of the KPC serine beta-lactamase (SBL) are available in the market, there is an urgent need for better broad spectrum inhibitors that would include SBLs of the OXA type that are rapidly spreading in Asia-Pacific and Europe.

Prevalence and geographical spread of the carbapenemase gene in Enterobacteriaceae (SENTRY survey; ASM microbe 2018)

Antabio is developing next-generation inhibitors of both MBL and SBL carbapenemases to restore the activity of carbapenem antibiotics in areas of high unmet need such as China and the Asia-Pacific region. Our potent and safe inhibitors are specifically designed to be combined with the well-known and widely used meropenem carbapenem in order to provide clinicians with efficient and ready-to-use solutions to treat life-threatening infections that are increasingly common in Chinese hospitals.

Pipeline



MBLi program: Metallo ß-lactamase inhibitor.

Antabio is developing a novel, safe and potent inhibitor of bacterial MBLs to be administered with a carbapenem for treating CRE infections in hospitalized patients. Antabio’s preclinical candidate ANT2681 potentiates carbapenem efficacy against NDM-CRE strains in animal infection models and restores carbapenem susceptibility in a broad range of MBL-producing clinical isolates (including all NDM variants that are prevalent in China). Pre-clinically ANT2681 shows superior NDM inhibition compared to competitors, including VNRX5133 recently in-licensed by Everest Medicines for development in China. Initiation of Phase 1 studies for ANT2681 is expected in 2020.


SBLi: Serine B-lactamase inhibitor

Antabio has discovered a novel and potent SBL inhibitor with broad coverage against key SBL enzymes, including ESBLs, KPC and OXA-type carbapenemases in Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa. Antabio’s candidate ANT3310 restores meropenem efficacy against both OXA and KPC CREs and is the only combination with potent activity vs OXA-producing A. baumannii, thus addressing a major unmet medical need in China, and also ranked n°1 global AMR priority by WHO. As such, ANT3310 is positioned to be the best SBLi in the market with a unique CRE and carbapenem-resistant A. baumannii (CRAB) target product profile.


PEi: Pseudomonas Elastase Inhibitors

This program, aimed at developing novel small molecule drugs for the treatment of chronic Pseudomonas infections in Cystic fibrosis (CF) patients, is currently funded by a CARB-X award (potentially $8.9 Million) to continue development up to clinical trials. ANTABIO has developed a safe and tractable lead series with potent whole cell activity against the Pseudomonas LasB elastase secreted by clinical CF isolates and excellent potential for inhaled administration.


IP

Antabio pursues an aggressive IP strategy to protect its drug discovery and development portfolio though novel composition of matter claims on selected series and claims on use of the compounds (and combinations thereof with relevant partner antibiotics). Our most advanced MBLi patent has been granted in the US, Europe, China & Japan, with India under examination. and China under examination.


Funding

Antabio has raised €35.6 million to date, of which €18.7 million in subsidies (including two Wellcome Trust and one CARB-X fundings) and €16.9 million in equity from private investors (including historical investor and ex-CEO of Geneva based OM-Pharma Christophe Ricard, and venture capital funds Omnes Capital, BNP Paribas Développement, Turenne Capital, Ixo Private Equity, IRDI Soridec and Galia Gestion).


Business model & partnering

Antabio is actively seeking a Chinese partner for its MBLi program and is offering a license for clinical development and commercialization of the product in China to interested parties with a clinical development track record in infectious diseases. Antabio’s candidate ANT2681 targets carbapenem resistance (CR) through inhibition of metallo betalactamases, in particular NDM, for which no inhibitors are currently available or under clinical development. Given the high and increasing incidence of MBL-mediated CR in China, ANT2681 is a compelling opportunity to address an urgent unmet medical need in the country. The preclinical development of our combination Meropenem-ANT2681 is well advanced with non-GLP toxicology completed and a 5kg technical batch for GLP studies produced. Our combination has an excellent drug profile and will enter clinical development in Europe 2020. Ideally clinical development in China will start at the same time.


Investment opportunity

Antabio is seeking to raise €15 million to take its portfolio of novel Gram-Negative anti-infective programs through phase 1 clinical stage. These funds will enable the parallel development a broad pipeline of novel antibiotics to address the urgent unmet needs of today and tomorrow. As the inevitable global antimicrobial resistance crisis materializes, the company will be ideally poised to provide critical healthcare solutions and create shareholder value.


Team

Antabio has built a best-in-class, international team with highly successful track records including former executives from Novexel, Galapagos, Merck, GSK and Astra Zeneca.

marc-lemonnier

Marc Lemonnier – Founding CEO

Gordon-Waldron

Gordon Waldron – CFO

helmuth

Helmuth van Es – CBO

martin_everett

Martin Everett – CSO

sabre

Carole A. Sable – Clinical Director

marc-lemonnier

Magdalena Zalacain – Preclinical R&D Director